Prostate Cancer Disappointment Means Lilly Might Finally Get The Point

 
• By Elizabeth Cairns

Point Biopharma’s radiopharmaceutical lags Novartis’s on PFS, and its commercial viability may be limited.  

Unhappy and disappointed customer giving low rating and negative feedback in survey, poll or questionnaire. Sad and dissatisfied man giving review about service quality. Bad user experience. - Image

More from Clinical Trials

More from R&D